1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. INTELLIA THERAPEUTICS INC
Intellia Therapeutics Inc
XNAS: NTLA
Weak Stock
Download real time
11.43-0.48(-4.03%)
59.54% Fall from 52W High
5.4M
XNAS Volume

XNAS 14 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Intellia Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Intellia Therapeutics Inc share price target, revenues, EPS, net income and more

Intellia Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEGATIVE

    Quarterly Revenue Intellia Therapeutics Inc Jun-2026 Quarterly Revenue is $8 Million which is growth of -46.2% YoY.

  • NEGATIVE

    Quarterly Net Profit Intellia Therapeutics Inc Jun-2026 Quarterly Net Profit is $-107 Million which is growth of -5.3% YoY.

Intellia Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
7.715.12313.814.216.612.99.1728.9-1.91213.6
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
120.4115.6121.7125.3124.2137.4149.3153.9146142.9138143.1145.9
Operating Profit
-112.8-100.5-98.7-111.5-110-120.8-136.5-144.8-139-114-139.9-131.1-132.3
⌄
5.85.26.56.77.48.610.612.112.412.612.512.712.7
Profit Before Tax
-106.6-96.2-95.8-101.3-101.3-114.3-128.9-135.7-147-107.4-132.2-122.2-123.7
Tax
-------------
⌄
-106.6-96.2-95.8-101.3-101.3-114.3-128.9-135.7-147-107.4-132.2-122.2-123.7
Diluted NI Avail to Com Stockholders Ann.
-106.6-96.2-95.8-101.3-101.3-114.3-128.9-135.7-147-107.4-132.2-122.2-123.7
Basic EPS
-0.8-0.8-0.8-0.9-1-1.1-1.3-1.3-1.5-1.1-1.5-1.4-1.4
Diluted EPS After ExtraOrdinary
-0.8-0.8-0.8-1-1-1.1-1.2-1.3-1.3-1.1-1.5-1.4-1.4
Number Of Shares End
133.5118.5116110.2103.7103.5101.91019795.590.588.688.2
Net Income Continuing Discontinued Operations
-106.6-96.2-95.8-101.3-101.3-114.3-128.9-135.7-147-107.4-132.2-122.2-123.7
Normalized Income
-88.9-81.9-75-85.2-80.6-90.4-86.2-93.1-85.8-67.2-97.1-86.9-87.3
Interest Income
5.85.26.56.77.48.610.612.112.412.612.512.712.7
Interest
-------------
Net Interest Income
5.85.26.56.77.48.610.612.112.412.612.512.712.7
EBIT
-112.4-101.4-102.3-108-108.7-122.9-139.5-147.8-159.4-120.1-144.6-135-136.3
EBITDA
-110.3-99.2-96.3-103.1-106.2-120.4-137-145.2-156.8-117.6-142.2-132.7-134.2
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
2.12.264.92.52.52.62.62.62.52.52.32.2
Profit From Continuing Operations
-106.6-96.2-95.8-101.3-101.3-114.3-128.9-135.7-147-107.4-132.2-122.2-123.7
Normalized EBITDA
-111-97.4-89.1-110-108.9-116.2-130.8-139.1-116.1-105.4-137.4-128.8-130.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Intellia Therapeutics Inc competitor comparison and performance snapshot within industry

Intellia Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Intellia Therapeutics Inc Dec-2025 Annual Revenue is $68 Million which is growth of 16.9% YoY.

  • POSITIVE

    Annual Net Profit Intellia Therapeutics Inc Dec-2025 Annual Net Profit is $-413 Million which is growth of 20.5% YoY.

Intellia Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
9.1%
3.1%
 67.757.936.352.133.15843.130.426.116.56
Cost Of Rev. Ann.
-
-
 -----------
Gross Profit Ann.
-
-
 -----------
Operating Exp. Ann.
-0.1%
21.2%
483508.7592.1551.6510.3300.9194.6149.5121.395.748.619.5
Operating Profit Ann.
-
-
-423.5-441-534.3-515.3-458.2-267.9-136.6-106.4-90.9-69.6-32.2-13.4
⌄
50.9%
64.8%
24.229.247.849.88.51.32.46.85.520.5-
Other Exp. Ann.
-
-
 -0.9-32.6-15.7-24.6-1.3------
PBT Ann.
-
-
-400-412.7-519-481.2-474.2-267.9-134.2-99.5-85.3-67.5-31.6-13.4
Tax Ann.
-
-
 ---------1
⌄
-
-
-400-412.7-519-481.2-474.2-267.9-134.2-99.5-85.3-67.5-31.6-12.4
Diluted NI Avail to Com Stockholders Ann.
-
-
-400-412.7-519-481.2-474.2-267.9-134.2-99.5-85.3-67.5-31.6-12.4
EPS Ann.
-
-
 -3.8-5.3-5.4-6.2-3.8-2.4-2.1-2-1.9-1.4-0.7
Diluted EPS Ann.
-
-
 -3.8-5.3-5.4-6.2-3.8-2.4-2.1-2-1.9-1.4-0.7
Number Of Shares End
12.6%
13.6%
 116101.990.581.374.461.349.444.239.23617.7
Total Exp. Ann.
-0.1%
21.2%
 508.7592.1551.6510.3300.9194.6149.5121.395.748.619.5
Net Income Continuing Discontinued Operations Ann.
-
-
-400-412.7-519-481.2-474.2-267.9-134.2-99.5-85.3-67.5-31.6-12.4
Normalized Income Ann.
-
-
-330.9-331.1-332.3-347-369.5-220.9-114.3-84.4-68.2-52.1-24.9-11.2
Interest Income Ann.
50.9%
64.8%
24.229.247.849.88.51.32.46.85.520.5-
Interest Ann.
-
-
 -----------
EBITDA Ann.
-
-
-408.9-432.1-556.5-522-475.1-262.3-130.3-100.8-86.4-66.6-31.1-13.1
Reconciled Cost Of Rev. Ann.
-
-
 -----------
Reconciled Depr. Ann.
27.9%
20.3%
15.215.910.397.66.96.35.64.531.10.3
Profit From Continuing Operations Ann.
-
-
-400-412.7-519-481.2-474.2-267.9-134.2-99.5-85.3-67.5-31.6-12.4
Normalized EBITDA Ann.
-
-
-407.6-424.2-491.4-506.2-437.1-261-130.3-100.8-86.4-66.6-31.1-13.1
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
16.9%
2Y CAGR
36.6%
3Y CAGR
9.1%
5Y CAGR
3.1%
7Y CAGR
12.1%
10Y CAGR
27.4%
Total Revenue Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
-14.1%
2Y CAGR
-4%
3Y CAGR
-0.1%
5Y CAGR
21.2%
7Y CAGR
22.7%
10Y CAGR
38.6%
Operating Expenses Annual Cr is falling faster than historical averages.

Intellia Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Intellia Therapeutics Inc Dec-2025 Total Shareholders Fund is $671 Million which is growth of -23.0% YoY.

  • NEGATIVE

    Total Assets Intellia Therapeutics Inc Dec-2025 Total Assets is $842 Million which is growth of -29.3% YoY.

Intellia Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-17.9%
4.5%
842.11,1911,3011,520.11,294.5676.3334.3347.3376.229982.1
⌄
-15.7%
2.7%
170.7319.1250.8284.5254.2149.364.469.475.689.114.8
⌄
-18.4%
5%
671.48721,050.21,235.61,040.2527.1269.9277.9300.6209.867.4
Total Capitalization Ann.
-18.4%
5%
671.48721,050.21,235.61,040.2527.1269.9277.9300.6209.867.4
Tangible Assets Ann.
-18.4%
5%
671.48721,050.21,235.61,040.2527.1269.9277.9300.6209.867.4
Working Capital Ann.
-27%
-5.2%
423.8529883.11,090.2643.5552.3253.9284.4323.5250.666.9
Invested Capital Ann.
-18.4%
5%
671.48721,050.21,235.61,040.2527.1269.9277.9300.6209.867.4
Tangible Book Value Ann.
-18.4%
5%
671.48721,050.21,235.61,040.2527.1269.9277.9300.6209.867.4
Borrowings Ann.
-10.6%
18.9%
93.3210.2115.4130.77439.318.4----
Net Debt Ann.
-
-
-----------
Share Issued Ann.
10.1%
11.9%
116.31029387.174.566.250.243.642.43634.3
Number Of Shares End
12.6%
13.6%
116101.990.581.374.461.349.444.239.23617.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-29.3%
2Y CAGR
-19.5%
3Y CAGR
-17.9%
5Y CAGR
4.5%
7Y CAGR
13.5%
10Y CAGR
26.2%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
-6.3%
2Y CAGR
-5%
3Y CAGR
-6.4%
5Y CAGR
10.1%
7Y CAGR
14.4%
10Y CAGR
25.5%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-23%
2Y CAGR
-20%
3Y CAGR
-18.4%
5Y CAGR
5%
7Y CAGR
13.4%
10Y CAGR
25.8%
Total ShareHolders Funds Annual is falling faster than historical averages.

Intellia Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Intellia Therapeutics Inc Book Value Per Share is $6 which is growth of -32.5% YoY.

  • NEUTRAL

    ROE Intellia Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Intellia Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--41.66%-34.11%-33.70%-27.19%-26.56%-29.21%-23.59%-20.01%-16.60%-26.71%
ROE Ann. %
-
-
--54.00%-42.10%-41.67%-34.18%-33.69%-36.34%-29.50%-26.46%-22.82%-42.40%
ROIC %
-
-
--13-12.5-10.4-7.1-9.2-10.2-7.7-10.4-5.1-7.8
OPM Ann. %
-
-
-651.67%-923.10%-1,420.51%-879.04%-810.37%-235.51%-246.78%-298.58%-266.32%-195.15%-221.86%
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
-0.10000.10.10.10.10.10.1
Working Capital Turnover Ann.
26%
14.9%
0.20.100.10.10.10.20.10.10.10.1
Quick Ratio Ann.
-
-
-5.58.29.569.387.911.29.17.2
Current Ratio Ann.
-
-
-5.88.79.66.19.68.1811.39.27.3
Interest Coverage Ratio Ann.
-
-
-----------
LT Debt To Equity Ann.
-
-
-0.20.10.10.10.10.1----
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Intellia Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Intellia Therapeutics Inc Dec-2025 Cash From Operating Activity is $-395 Million which is growth of -13.1% YoY.

  • POSITIVE

    Net Cash Flow Intellia Therapeutics Inc Dec-2025 Net Cash Flow is $-35 Million which is growth of 6.2% YoY.

Intellia Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-394.7-348.9-394.1-333.3-225-49.9-103.2-61.3-65.336.1-1.8
⌄
12.5%
-
228125.6-31.4160.3-550.8-214.525.2-260.8-10.1-6.2-2.6
⌄
-39.1%
-18.8%
131.5185.8130.3583736.7371.876.440.2143167.370.3
Cash Plus Cash Eqv. End Of Year Ann.
-32.1%
0.4%
167.6202.8240.4535.5125.5164.657.258.9340.7273.175.8
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-35.2-37.6-295.1410-39.1107.4-1.6-281.867.6197.366
Cash Plus Cash Eqv. Begin Of Year Ann.
17.3%
28.8%
202.8240.4535.5125.5164.657.258.9340.7273.175.89.8
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
-----------
Capex Ann.
-
-
-1.1-5.8-14-58.4-12.8-3.6-6.8-6.4-10.1-6.2-2.6
Issuance Of Capital Stock Ann.
-39%
-18.6%
128.2176.9119.8565.8693.6358.772.329141170.574.7
Issuance Of Debt Ann.
-
-
-----------
Repayment Of Debt Ann.
-
-
-----------
Repurchase Of Capital Stock Ann.
-
-
--------0.1-2.7
Free Cash Flow Ann.
-
-
-395.9-354.7-408.1-391.7-237.8-53.5-110-67.6-75.429.9-4.3
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Investing Act. Ann.
1Y CHG
81.5%
3Y CAGR
12.5%
Cash from Investing Activity Annual growth is stable compared to historical averages.
Cash from Financing Act. Ann.
1Y CHG
-29.2%
2Y CAGR
0.5%
3Y CAGR
-39.1%
5Y CAGR
-18.8%
7Y CAGR
18.4%
10Y CAGR
6.5%
Cash from Financing Annual Activity is falling faster than historical averages.
×